H.C. Wainwright analyst Mike Colonnese lowered the firm’s price target on Bitdeer (BTDR) to $20 from $21 and keeps a Buy rating on the shares ...

H.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (RCUS) to Buy from Neutral with a price target of $24, up from $18. The ARC-20 ...

Analysts at HC Wainwright issued their Q4 2026 EPS estimates for Balchem in a research note issued to investors on Monday, February 24th. HC Wainwright analyst R. Selvaraju anticipates that the basic ...

Fintel reports that on February 25, 2025, HC Wainwright & Co. initiated coverage of Centrus Energy (NYSEAM:LEU) with a Buy ...

HC Wainwright reiterated their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. Separately ...

Fintel reports that on February 24, 2025, HC Wainwright & Co. initiated coverage of Veritone (NasdaqGM:VERI) with a Buy ...

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...

Highlights,Adjusted Q1 2025 EPS projections for Bausch + Lomb as analysts slightly reduce expectations.,Diverse analyst ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...